Mark R. Thursz

Mark R. Thursz

St. Mary's Hospital, Praed Street
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 257 publications

Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026.

Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026.

Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: June 03, 2026

From Evidence to Action: The WHO-Imperial-EASL Collaborating Centre on Steatotic Liver Disease.

From Evidence to Action: The WHO-Imperial-EASL Collaborating Centre on Steatotic Liver Disease.

Journal: Journal of hepatology
Published: May 22, 2026

Effects of GLP-1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD: A Systematic Review.

Effects of GLP-1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD: A Systematic Review.

Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: February 13, 2026

Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic.

Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic.

Journal: BMJ open
Published: February 05, 2026

Disordered Bile Acid Metabolism in Alcohol-Related Hepatitis.

Disordered Bile Acid Metabolism in Alcohol-Related Hepatitis.

Journal: Alimentary pharmacology & therapeutics
Published: January 09, 2026

Nucleos(t)ide withdrawal vs Nucleos(t)ide withdrawal with adjuvant pegylated-interferon in HBeAg-negative hepatitis B virus infection (NUC-B Trial).

Nucleos(t)ide withdrawal vs Nucleos(t)ide withdrawal with adjuvant pegylated-interferon in HBeAg-negative hepatitis B virus infection (NUC-B Trial).

Journal: Hepatology (Baltimore, Md.)
Published: September 19, 2025

Unveiling the Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a Nationwide Cohort.

Unveiling the Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a Nationwide Cohort.

Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: August 08, 2025

Operational considerations for the running of an NHS faecal microbiota transplant service.

Operational considerations for the running of an NHS faecal microbiota transplant service.

Journal: The Journal of hospital infection
Published: June 12, 2025

Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B.

Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: March 06, 2025

Letter: Predictors of Corticosteroid Response in Alcohol-Related Hepatitis.

Letter: Predictors of Corticosteroid Response in Alcohol-Related Hepatitis.

Journal: Alimentary pharmacology & therapeutics
Published: February 24, 2025

An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice.

An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: February 11, 2025

Larsucosterol for the Treatment of Alcohol-Associated Hepatitis.

Larsucosterol for the Treatment of Alcohol-Associated Hepatitis.

Journal: NEJM evidence
Published: January 28, 2025
Showing 1-12 of 257

Last Updated: 09/26/2026